Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in December

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 15th total of 4,910,000 shares. Based on an average daily trading volume, of 976,100 shares, the short-interest ratio is presently 5.8 days.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick acquired 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter valued at approximately $50,000. HB Wealth Management LLC bought a new stake in shares of Immunic during the 4th quarter valued at approximately $81,000. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Trading Down 3.4 %

IMUX stock traded down $0.03 during trading hours on Friday, hitting $0.95. 1,720,429 shares of the stock were exchanged, compared to its average volume of 781,842. Immunic has a 12 month low of $0.95 and a 12 month high of $2.11. The firm has a market capitalization of $85.85 million, a P/E ratio of -0.77 and a beta of 1.88. The company has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.31.

Analyst Ratings Changes

IMUX has been the topic of several recent research reports. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. Finally, HC Wainwright initiated coverage on Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.